C001: Avastin Biosimilar Stable Cell Line (CHO)
The yield of Avastin biosimilar from the CHO stable cell line was above 1.7 g/L in a 750 liter manufacturing.
C001P: Bevacizumab Biosimilar, Human VEGF Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody generated from the same parent mouse antibody as ranibizumab.
Specificity/Sensitivity: The monoclonal antibody bevacizumab biosimilar specifically binds to the human VEGF-A.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by bevacizumab.C069P: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade brolucizumab biosimilar specifically binds to the human vascular endothelial growth factor A (VEGF-A).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by brolucizumab.C005: Lucentis Biosimilar Cell Line (E. coli)
The yield of Lucentis biosimilar from E.coli was above 36 mg/L in a 7.5 liter manufacturing.
C005P: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)
Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.
Specificity/Sensitivity: The research grade Fab protein ranibizumab specifically binds to the human VEGF-A.
Applications: Functional assay, neutralization.BP000027-CYT-200: Recombinant Human VEGF (121 a.a.) Protein, Sf9
Source: Sf9, Insect Cells-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 2-5 ug/ml corresponding to a Specific Activity of 200,000-500,000 IU/mg.
Purity: >90% by SDS-PAGE and RP-HPLC.BP000027-CYT-225: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein, HEK
Source: HEK 293 (Human Embryonic Kidney cell line)-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-6 ug/ml corresponding to a Specific Activity of 166,667-1,000,000 IU/mg.
Purity: > 95% by SDS-PAGE.BP000027-CYT-226: Recombinant Mouse Vascular Endothelial Growth Factor (VEGF) Protein, Sf9
Source: Baculovirus Sf9 cells-derived.
The ED50 range, determined by the dose-dependent proliferation of human umbilical vein endothelial cells (HUVEC) (measured by 3H-thymidine uptake) is 1-2 ug/ml, corresponding to a specific activity of 1x106 Units/mg.
Purity: > 95% by SDS-PAGE and RP-HPLC.BP000027-CYT-241: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein
Source: E. coli-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-8 ug/ml corresponding to a Specific Activity of 125,000-1,000,000 IU/mg.
Purity: > 98% by SDS-PAGE and RP-HPLC.BP000027-CYT-260: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein, CHO
Source: Chinese Hamster Ovarian Cell-derived.
Determined by its ability to stimulate 3H-Thymidine incorporation in human ublical vein endothelial cells, the ED50 for this effect was found to be 2-6 ng/ml corresponding to a Specific Activity of 166,667-500,000 IU/mg.
Purity: > 97% by SDS-PAGE and RP-HPLC.